EMA OKs New Option for Pulmonary Fibrosis
The European Medicines Agency has recommended the approval of Jascayd for treating idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. This decision will be forwarded to the European Commission for final authorization. Jascayd, containing the active substance nerandomilast, has shown promising results in clinical trials, particularly in reducing lung function decline in patients.
- ▪Jascayd is intended for adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- ▪The drug is an immunosuppressant that inhibits phosphodiesterase 4 and has antifibrotic effects.
- ▪Clinical trials demonstrated that patients taking nerandomilast experienced significantly less decline in lung function compared to those on placebo.
Opening excerpt (first ~120 words) tap to expand
The European Medicines Agency (EMA) has recommended granting marketing authorization for Jascayd (nerandomilast, Boehringer Ingelheim International GmbH) to treat adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).The opinion will now be sent to the European Commission for a decision on an EU-wide marketing authorization. IPF is a chronic, progressive, fibrosing, interstitial pneumonia and the most common type of pulmonary fibrosis. PPF is a distinct form of progressive and fibrotic disease that occurs in cases of interstitial lung disease other than IPF. Both conditions typically occur in older adults.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
